Event Date/Time: Jan 27, 2004 End Date/Time: Jan 29, 2004
Report as Spam


Welcome to your annual opportunity to take the pulse of the drug delivery industry, capitalize on avenues of communication and gain the information you need to get one step closer to the deal. The 8th annual event understands your primary concerns: product differentiation, productivity, competitive intelligence, and the opportunity to meet decision makers, resulting in a premier industry gathering. Whether your objective is a traditional pharma/drug delivery deal or whether you are evaluating new alliances involving consumer products, biotech compounds or generic drugs, the 8th annual DDP is your portal to prospecting new business development initiatives and developing the relationships that deliver them.

Announcing the 2004 Keynote Speakers:
Gary Cupit, PhD, Senior Vice-President, Global Business Development, Novartis provides an overview of the macro forces impacting the drug development and delivery and the alliances that support it

Roger Longman, Managing Partner, Windhover Information recaps recent innovative deals and deal structures influencing market changes

E.M. (Mick) Kolessa, PhD, Managing Partner, Medical Marketing Economics addresses pricing and reimbursement trends, critical issues to the success of innovative drug products

Frank R. Lichtenberg, PhD, Courtney C. Brown Professor of Business, Columbia University offers quantitative research that illustrate that pharmaceutical innovation lowers healthcare costs

Announcing the 2004 Featured Presentations:
Eugene Cooper, Former Executive Vice President & Chief Technical Officer, Elan Drug Delivery Technologies/Nanosystems presents the role of nanoparticles for the delivery of poorly soluble drugs and what was needed to bring this new technology into the industry

Wayne A. Rosenkrans, Jr., PhD, Director, Intelligence Affairs, Strategic Planning and Marketing Operations, AstraZeneca Pharmaceuticals demonstrates the use and importance of competitive intelligence tools to furthering your business goals

David M. Steinberg, Managing Director, Equity Research, Specialty Pharmaceuticals and Drug Delivery, Deutsche Banc Alex Brown assesses the current market value and future potential of the drug delivery sector

Leverage In-Depth Topic Coverage at our 2004 Pre-Event Workshops:

B1: Optimizing Drug Delivery Partnerships with Consumer Products and OTC Companies: Enhancing Relationships and Realizing Opportunity
B2: Next Generation Bioavailability Enhancement
B3: Creating Value from Drug Delivery Partnership Agreements
B4: Delivering Drug Delivery: Securing Your Innovative Drug Delivery Product
B5: Drug Delivery Start-Ups and Spin-Offs: What Factors Lead to Success?
B6: Merging Protein and Peptide Drugs and Delivery Systems

New Concurrent Tracks in 2004 for Customized Information-Gathering

Track A: Innovative Business Development
Track B: Innovative Technology that Fuels Deals: Part I
Track C: Strategic Product Development and Lifecycle Management
Track D: Delivering to Biotechnology
Track E: Innovative Technology that Fuels Deals: Part II
Track F: Responding to and Capitalizing the Generic Drug Market

We have included additional time in the program for one-on-one business development meetings with existing or potential new partners and for visiting the exhibit hall. Thanks to the generous support of our event partners, enjoy refreshments during breakfasts, luncheons, event networking breaks and evening receptions in our exhibit hall. This is your time to capitalize on a tremendous deal-developing experience. We look forward to meeting you in Beverly Hills January 27-29, 2004.